Pfizer : Oncology Innovation Day Presentation

Oncology Innovation Day

Accelerating the Next Generation of

Cancer Breakthroughs

0 2 . 2 9 . 2 0 2 4

Welcome

Francesca DeMartino

Chief Investor Relations Officer

Forward-Looking Statements, Non-GAAP Financial Information and Other Notices

Our discussions during Oncology Innovation Day will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-looking statements about, among other topics, Pfizer Oncology; our anticipated operating and financial performance, including financial guidance and projections; changes to Pfizer's commercial organization; reorganizations; business plans, strategy, goals and prospects, including our 2030 goals; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, size and utilization rates, growth, performance, timing of exclusivity and potential benefits; strategic reviews, capital allocation objectives, an enterprise-wide cost realignment program, dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, including our recent acquisition of Seagen and our ability to successfully capitalize on these opportunities; manufacturing and product supply; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results. Among other things, statements regarding revenue and earnings per share growth; anticipated operating and financial performance; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the potential and timing for the initiation and progress of clinical trials and data read-outs from trials; the timing and potential for the submission of applications for and receipt of regulatory approvals; the timing and potential for product launches and commercialization; expected profile and labeling; potential revenue; expected breakthrough, best- or first-in-class or blockbuster status or expected market entry of our medicines; potential patients reached; potential portfolio composition; the regulatory landscape; and the competitive landscape are forward-looking and are estimates that are subject to change and subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success, demand, availability of supply, and competitive and market dynamics. These statements may be affected by underlying assumptions that may prove inaccurate or incomplete, and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (2023 Form 10-K) and its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in Pfizer's subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Potential risks and uncertainties also include global economic and/or geopolitical instability, foreign exchange rate fluctuations and inflationary pressures and the impact of COVID-19 on our sales and operations, including impacts on employees, manufacturing, supply chain, marketing, research and development and clinical trials. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.

The discussions during Oncology Innovation Day may include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). Additional information regarding non-U.S. GAAP financial measures can be found in Pfizer's 2023 Form 10-K. Any non-U.S. GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by U.S. GAAP, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies.

Today's discussions and presentation are intended for the investor community only; they are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. Definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data as they may be confounded by various factors and should be interpreted with caution. All trademarks in this presentation are the property of their respective owners.

Certain of the products and product candidates discussed during Oncology Innovation Day are being co-researched,co-developed and/or co-promoted in collaboration with collaboration partners for which Pfizer's rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets. These include Xtandi (with Astellas Pharma Inc.), Padcev (with Astellas Pharma Inc.), Adcetris (with Takeda Pharmaceutical Company Limited), Tivdak (with Genmab A/S and Zai Labs (Hong Kong) Limited), Orgovyx (with Sumitomo Pharma America, Inc.), Vepdegestrant (with Arvinas, Inc.), Disitamab vedotin (with RemeGen Co., Ltd.), Braftovi and Mektovi (with Pierre Fabre Medicament SAS, Ono Pharmaceutical Co., Ltd. and Medison), CEACAM5C (with Sanofi), and EGFRd2 (with LAVA). Please see Pfizer's 2023 Form 10-K for additional information.

3

Today's Agenda

1:05-1:30PM	Pfizer Oncology Vision	4:00-4:15PM	Hematology-Oncology
	Chris Boshoff		Chris Boshoff
1:30-2:05PM	Genitourinary Cancer	4:15-4:45PM	Next-Generation Opportunities
	Roger Dansey and Thomas Powles		Jeff Settleman
2:05-2:30PM	Thoracic Cancer	4:45-5:00PM	Pfizer Oncology Commercial Outlook
	Megan O'Meara		Suneet Varma
2:30-3:00PM	Q&A Session #1	5:00-5:30PM	Q&A Session #2
	Panel		Panel
3:00-3:30PM	Break	5:30-5:35PM	Summary
			Chris Boshoff
3:30-4:00PM	Breast Cancer		Closing Remarks
	Roger Dansey		Albert Bourla

All times are EST.	4

Today's Speakers

Chris Boshoff	Roger Dansey	Megan O'Meara	Jeff Settleman	Suneet Varma	Thomas Powles
MD PhD	MD	MD	PhD	MBA	MD PhD

Chief Oncology	Chief Development	Head, Early-Stage	Chief Scientific	Commercial President,	Professor of
Officer	Officer,	Development,	Officer,	Pfizer Oncology	Genitourinary
	Pfizer Oncology	Pfizer Oncology	Pfizer Oncology		Oncology​, University
					of London and Barts
					Cancer Centre​

5

Pfizer Oncology Vision

Chris Boshoff

Chief Oncology Officer

P F I Z E R O N C O L O G Y V I S I O N

Accelerate breakthroughs that help people with cancer globally live better and longer lives​

7

Cancer Remains One of the Greatest Health Challenges of Our Lifetime

~2 million

New cancer cases in the US expected in 20241

~20million

New cancer cases globally in 20222

~10million

Deaths from cancer globally in 2022,2 and >600K deaths expected in the US this year1

1. American Cancer Society 2024 Facts & Figures. 2. International Agency for Research on Cancer (IARC) Global Cancer Observatory.

8

175 years of

delivering

breakthroughs that

change patients'

lives

Expertise + Innovation + Scale

Breakthrough Medicines

Pioneers of ADC

technology to improve

and extend lives of people with cancer

ADC, antibody-drug conjugate.	9

01	+	02	+	03
Expertise	Innovation	Scale

Deep insights	Tomorrow's medicines
Best of both	Robust R&D engine and
organizations,	pipeline, focused on
with exceptional talent	execution and next-
and extensive	generation breakthroughs
experience

Global impact

New end-to-end organization, with industry- leading commercial and manufacturing capabilities

10